"Global Cancer Immunotherapy Market Opportunity, Dosage, Price and Clinical Trials Insight 2026" Report Highlights:
Global Cancer Immunotherapy Market Opportunity: > US$ 200 Billion
Cancer Immunotherapy Clinical Trials: > 2300 Drugs In Trials
Commercially Available Cancer Immunotherapies: > 120
Cancer Vaccines Market Opportunity: > US$ 20 Billion
Cancer Monoclonal Antibodies Market Opportunity: > US$ 90 Billion
Marketed Cancer Monoclonal Antibodies': > 70 mAbs
Sales, Market Opportunity, Dosage and Price Data: 300 Graphs/Charts
Clinical Trials Insight By Phase, Company, Patient Segment, Drug Class
The research report “Global Cancer Immunotherapy Market Opportunity, Dosage, Price and Clinical Trials Insight 2026” discusses the implications that the recent scientific research and development has brought, in context to the ongoing trends and current size of the cancer immunotherapy at global and regional level. Additionally, the report depicts the nature of the therapies and the structures that are followed by the cancer immunotherapy approach, with detailed profiles of the pharmaceutical companies that are the keynote representer of immunotherapy products in the market.
"Cancer Immunotherapy Has Emerged As Next Growth Frontier With US$ 200 Billion In Market Opportunity For Multiple Stake Holders Involved In The Research and Development Of Anti Cancer Therapies"
The immunotherapy defends the normal cells by activating the body’s immune system against the cancerous cells. The immunotherapy attractively summons the manipulated body’s own natural immune cells and causes the eviction of the cancer cells. The cancer immunotherapy techniques such as T-cell therapy, Immune checkpoint inhibitors, Cancer vaccines, Monoclonal Antibodies and many more have offered the cancer patients with no or less hope and with substantial benefit of meaningful improvements. The growth of the respective market is attributed to the advantage that it provides of being a potential one-time treatment with long and durable response.
Different cancer immunotherapies have been developed and successfully marketed across the globe for various malignancies. They may differ in modality but all of them have some common features due to which they are in high demand among cancer patients. Development of results is apparently rapid than other cancer treatment leading to quick alleviation of clinical symptoms. As a result, more cancer patients want them to improve their medical condition in shorter time.
Improved anti-cancer efficacy is another major benefit of cancer immunotherapies which is not offered by other modalities. Fewer side effects are observed during cancer immunotherapy treatment resulting in higher tolerability and improved quality of life. Relapse prevention and increased progression free survival are also improved resulting in increased demand for cancer immunotherapies. Investigators are trying to decipher more underlying principles of cancer immunotherapies in order to offer better medical care to patients.
The aim with which the cancer immunotherapy approach came into existence was to escalate the process of cancer treatment which largely went unnoticed during usage of traditional technologies. Advanced manipulations in all the therapies of cancer immunotherapy have placed the approach above all the other available therapies for cure of cancer. The ease and the technological performance of the therapies results in long term survival of the cancer patients and a more comfortable after treatment life due to the absence of unwanted chemicals in the body and thus leading to less severe side effects. The approach has enhanced the already existing cancer treatment techniques and has marked itself as an important discovery in the field of oncology.
The strategies that are employed by the immunotherapy approach are playing a very important part in the overall medication for the cancer and that has led to the successful and rapid expansion of the overall immunotherapy market in a very short period of time. The cancer immunotherapy market is driven by the fact that the methodologies working under it have a strong clinical pipeline among which monoclonal antibodies constitutes the most widely accepted immunotherapeutic approach at the global level. The impressive rate at which the market is growing is representing a state of progress that the approach will follow in the near future.
Immunotherapy for Cancer
1.1 Introduction to Cancer Immunotherapy
1.2 Advancement of Cancer Immunotherapy
Types of Cancer Immunotherapy
2.1 Specific Cancer Immunotherapy
2.1.1 Cancer Vaccines
2.1.2 Monoclonal Antibodies
2.2 Non-Specific Cancer Immunotherapy
2.2.1 Adoptive Cell Transfer Immunotherapy
2.2.2 Immune Checkpoint Inhibitors
Dynamics of Global Cancer Immunotherapy Landscape
3.1 Favorable Developmental and Commercialization Parameters
3.2 Issues to be Resolved in Expansion of Immunotherapy Horizon
Cancer Vaccines: Transforming The Immunotherapy Landscape
4.1 Prologue of Cancer Vaccines
4.2 Cancer Vaccines in Immunotherapy
4.3 Commercialization of Cancer Vaccines
Monoclonal Antibodies: New Era of Immunotherapy
5.1 Rudiments of Monoclonal Antibodies
5.2 Advents of Monoclonal Antibodies
5.3 Commercial Aspects of Monoclonal Antibodies
Trails of T-Cell Therapies
6.1 Adoptive Cell Transfer Technology
6.2 Strategies of Adoptive Cell Transfer
6.3 Commercial Aspects of Adoptive Cell Therapy
Application of Immune Checkpoint Inhibitors in Immunotherapy
7.1 Prelude to Immune Checkpoint Inhibitors
7.2 Implications of Immunecheck Point Inhibitors
7.3 Commercial Aspects of Immune Checkpoint Inhibitors
Role of Immunomodulators in Cancer Immunotherapy
8.1 Perspective of Immunomodulators
8.2 Clinical Aspects of Immunomodulators
8.3 Commercial Aspects of Immunomodulators
Development of Oncolytic Viral Immunotherapy
9.1 Concept to Oncolytic Viruses
9.2 Potential Approaches of Oncolytic Viruses
9.3 Commercial Aspects of Oncolytic Viruses
Cytokines and Cancer Immunotherapy
10.1 Fundamentals of Cytokines
10.2 Classification of Cytokines
10.3 Commercial Aspects of Cytokines
Interferons in Immunotherapy
11.1 Potentials of Interferons
11.2 Classification of Interferons
11.3 Clinical Applications of Interferons
Interleukins in Immunotherapy
12.1 Potentials of Interleukins
12.2 Clinical Applications of Interleukins
GM-CSF in Immunotherapy
13.1 Potentials of GM-CSF
13.2 Clinical Applications of GM-CSF
Market Aspects of Cancer Immunotherapy
14.1 Current Market Trends
14.2 Economic Aspects of Cancer Immunotherapy
14.3 Cancer Immunotherapy Cost by Product
Cancer Immunotherapy Pipeline Overview
15.1 By Drug Class
15.2 By Phase
15.3 By Company
15.4 By Target
15.5 By Patient Segment
Cancer Immune Check Point Inhibitors - Availability, Price, Dosage and Sales Analysis
16.1 Keytruda (Pembrolizumab)
16.2 Yervoy (Ipilimumab)
16.3 Opdivo (Nivolumab)
16.4 Tecentriq (Atizolizumab)
16.5 Bavencio (Avelumab)
16.6 Imfinzi (Darlumuvab)
16.7 Libtayo (Cemiplimab)
Cancer Monclonal Antibody Market - Availability, Price, Dosage and Sales Analysis
17.1 Herceptin (Trastuzumab)
17.2 Avastin (Bevacizumab)
17.3 MabThera/Rituxan (Rituximab)
17.4 Erbitux (Cetuximab)
17.5 Vectibix (Panitumab)
17.6 Arzerra (Ofatumumab)
17.7 Gazyva (Obinutuzumab)
17.8 Perjeta (Pertuzumab)
Bispecific Antibody Market - Availability, Price, Dosage and Sales Analysis
18.1 Blincyto (Blinatumomab)
Cancer Vaccine Market - Availability, Price, Dosage and Sales Analysis
19.1 Gardasil and Gardasil 9
19.2 Cervarix
19.3 Provenge (Sipuleucel – T)
19.4 Vaxira (Racotumomab)
19.5 CreaVax-RCC
Cancer Cytokines Drugs Market - Availability, Price, Dosage and Sales Analysis
20.1 Proleukin (Aldeslukin)
20.2 Intron A (Interferon Alpha-2b)
20.3 PegIntron (PegInterferon alpha-2b)
20.4 Sylatron (Peginterferon Alpha-2b)
20.5 Betaseron (Interferon Beta-1b)
20.6 Actimmune (Interferon Gamma-1b)
20.7 Ontak (Denileukin Diftitox)
Oncolytic Virus Market - Availability, Dosage, and Price Analysis
21.1 Imlygic
CAR-T Cell Therapy - Availability, Dosage, Price and Sales Analysis
25.4 Dendritic Cell Vaccine (CreaVax-HCCandreg;, CreaVax-PCandreg; and CreaVax-RCCandreg;)
25.5 Human Papillomavirus Vaccine Quadrivalent (Gardasilandreg;/Silgardandreg;)
25.6 Human Papillomavirus Vaccine Recombinant Bivalent (Cervarixandreg;)
25.7 Immuvac / Cadi 05
25.8 Immucyst / TheraCys
25.9 Melanoma Vaccine (MVaxandreg;)
25.10 Melanoma Vaccine (Melacineandreg;)
25.11 Racotumomab (Vaxiraandreg;)
25.12 Reniale
25.13 Sipuleucel-T (Provengeandreg;)
25.14 Tertomotide (LucaVax)
25.15 Vitespen (Oncophageandreg;)
Marketed Cancer Monoclonal Antibodies
26.1 Bevacizumab
26.2 Trastuzumab Emtansine
26.3 Trastuzumab Subcutaneous
26.4 Brentuximab Vedotin
26.5 Catumaxomab
26.6 Ipilimumab
26.7 Nivolumab
26.8 Pembrolizumab
26.9 Pertuzumab
26.10 Rituximab
26.11 Trastuzumab
26.12 Gemtuzumab Ozogamicin
26.13 Others
Global Cancer Immunotherapy Market Future Prospects
Competitive Landscape
28.1 Abbvie
28.2 Advaxis
28.3 Altor BioScience
28.4 Amgen
28.5 Biogen Idec
28.6 Biogenomics
28.7 Celldex Therapeutics
28.8 Dendreon Corporation
28.9 Eli Lilly
28.10 Expression Genetics
28.11 Galena Biopharma
28.12 Genmab
28.13 Gilead Sciences
28.14 GlaxoSmithKline
28.15 ImmunoCellular Therapeutics
28.16 ImmunoGen
28.17 Inovio Pharmaceuticals
28.18 IRX Therapeutics
28.19 Merck
28.20 NeoStem Oncology
28.21 NewLink Genetics
28.22 Northwest Biotherapeutics
28.23 Novartis
28.24 Peregrine Pharmaceuticals
28.25 Pfizer
28.26 Philogen
28.27 Regulon
28.28 Roche
28.29 Seattle Genetics
28.30 ZymoGenetics
Figure 1-1: Evolutionary Trails of Cancer Immunotherapy
Figure 1-2: Layout of Necessity of Cancer Immunotherapies for Cancer Treatment
Figure 1-3: Potential Benefits of Cancer Immunotherapies
Figure 2-1: Classification of Cancer Immunotherapies
Figure 2-2: Categorization of Specific Immunotherapy
Figure 2-3: Non-Specific Cancer Immunotherapies
Figure 3-1: Favorable Cancer Immunotherapy Market Parameters
Figure 3-2: Cancer Immunotherapy Commercialization Challenges
Figure 4-1: Categorization and Function of Cancer Vaccines
Figure 4-2: Mechanism of the Cancer Vaccine towards Tumor Eradication
Figure 4-3: Global - Cancer Vaccines Market (US$ Billion), 2018-2026
Figure 5-1: Process of Manufacturing of Monoclonal Antibody
Figure 5-2: Principles of Monoclonal Antibodies
Figure 5-3: Evolution of Monoclonal Antibody over Generations
Figure 5-4: Classification of Monoclonal Antibodies
Figure 5-5: Representation of Mechanism of Alemtuzumab
Figure 5-6: Representation of Mechanism of Ibritumomab Tiuxetan
Figure 5-7: Representation of Mechanism of Blinatumomab
Figure 5-8: Global - Market for Cancer Monoclonal Antibodies (US$ Billion), 2018-2026
Figure 6-1: Benefit of Adoptive Cell Transfer Immunotherapy
Figure 6-2: Systematic Representation of Adoptive T-Cell Therapies
Figure 6-3: Three Adoptive Cell Transfer Strategies for Cancer Immunotherapy
Figure 6-4: Tumor-Infiltrating Lymphocytes in Adoptive Cell Transfer
Figure 6-5: Mechanism of CAR Modified T-Cells
Figure 6-6: Genetically Engineered TCR for Cancer Immunotherapy
Figure 6-7: Global - Predictive Market of CAR T-Cell Therapeutics (US$ Million), 2018-2026
Figure 7-1: Benefits of Immune Checkpoint Inhibitors
Figure 7-2: Implication of Adaptive Immune Resistance Mechanism
Figure 7-3: Mechanism of Ipilimumab
Figure 7-4: Layout of Mechanism of Nivolumab
Figure 7-5: Mechanism of Pembrolizumab
Figure 7-6: Global - Immune Check Point Inhibitors Market (US$ Billion), 2018-2026
Figure 8-1: Functions of Immunomodulators
Figure 8-2: Benefits of Immunomodulators
Figure 8-3: Layout of the Challenges of Immunomodulators
Figure 8-4: Properties of Thalidomide
Figure 8-5: Mechanism of Lenalidomide In Vivo
Figure 8-6: Mechanism of Lenalidomide in Vitro
Figure 8-7: Mechanism of Pomalidomide
Figure 8-8: Global - Immunomodulators Market for All Indications (US$ Billion), 2018-2026
Figure 9-1: Demonstration of Categorization of Oncolytic Viruses
Figure 9-2: Potential Advantages of Oncolytic Viruses over Conventional Therapies
Figure 9-3: Global - Predicted Market Share of Oncolytic Viral Therapies (US$ Million), 2018-2026
Figure 10-1: Layout of Functions Performed by Cytokine
Figure 10-2: Benefits of Cytokines in Cancer Immunotherapy
Figure 10-3: Classification of Cytokine Receptor Family
Figure 10-4: Percentage Share of the Cancer Immunotherapies by the Technology
Figure 11-1: Layout of Functions of Interferon
Figure 11-2: Classification of Interferons on the Basis of Types of Genes
Figure 11-3: General Mechanism of Interferons
Figure 11-4: Mechanism of Interferon Alfa-n3
Figure 11-5: Aspects of Peginterferon Alfa-2a
Figure 11-6: Applications of Interferon Beta 1a
Figure 11-7: Potentials of Interferon Alfa-2b
Figure 12-1: Functions of Interleukin
Figure 12-2: Potentials of Interleukins in Cancer Immunotherapy
Figure 12-3: Clinical Potentials of Proleukin
Figure 12-4: Clinical Potentials of Denileukin Diftitox
Figure 13-1: Potential Applications of GM-CSF
Figure 13-2: Mechanism of Sargramostim
Figure 14-1: Global - Cancer Immunotherapeutic Market (US$ Billion), 2018-2026
Figure 14-2: Expected Cancer Treatment Cost (US$ Billion), 2016-2022
Figure 14-3: Comparative Analysis of Available Cancer Treatments
Figure 14-4: Major Approved Immunotherapeutic Drugs
Figure 14-5: Annual per Patient Drug Expenditure of Immunotherapy
Figure 15-1: Global - Cancer Vaccine Clinical Pipeline by Phase (%), 2020 - 2026
Figure 15-2: Global - Cancer Vaccine Clinical Pipeline by Phase (Number), 2020 -2026
Figure 15-3: Global - Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2020 -2026
Figure 15-4: Global - Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2020 -2026
Figure 15-5: Global - Cancer Cell Therapies Clinical Pipeline by Phase (%), 2020 -2026
Figure 15-6: Global - Cancer Cell Therapies Clinical Pipeline by Phase (Number), 2020 -2026
Figure 15-7: Global - Cancer Immunomodulators Clinical Pipeline by Phase (%), 2020 - 2026
Figure 15-8: Global - Cancer Immunomodulators Clinical Pipeline By Phase (Number), 2020 - 2026
Figure 15-9: Global - Cancer Immunotherapy Clinical Pipeline by Phase (Number), 2020 -2026
Figure 15-10: Global - Cancer Immunotherapy Clinical Pipeline by Company (Number), 2020 -2026
Figure 15-11: Global - Cancer Immunotherapy Clinical Pipeline by Target (Number), 2020 -2026
Figure 15-12: Global - Cancer Immunotherapy Clinical Pipeline by Patient Segment (Number), 2020 -2026
Figure 16-1: Keytruda – Patent Expiration Year by Region
Figure 16-2: Keytruda – Price for 4ml and 8ml Supply and Price per ml of Intravenous Injection (US$), January’2020
Figure 16-3: Keytruda – Duration of Single Treatment Cycle and Full Treatment of Melanoma and Other Cancers (Weeks), January’2020
Figure 16-4: Keytruda – Cost of Single and Full Treatment using Powder of Injection (US$), January’2020
Figure 16-5: Keytruda - Cost of Single and Full Treatment using Solution of Injection (US$), January’2020
Figure 16-6: Keytruda – Annual Sales Value (US$ Billion), 2016, 2017 and 2018
Figure 16-7: Keytruda – Quarterly Sales Value (US$ Billion), Q1-Q3, 2018 and 2019
Figure 16-8: Yervoy – US and Europe Exclusivity Expiration Year
Figure 16-9: Yervoy - Price for 10ml Supply and Price per ml 5mg/ml Intravenous Injection (US$), January’2020
Figure 16-10: Yervoy – Price for 40ml Supply and Price per ml 5mg/ml Intravenous Injection (US$), January’2020
Figure 16-11: Yervoy – Duration of Single Treatment Cycle and Full Treatment of Metastatic Melanoma (Weeks), January’2020
Figure 16-12: Yervoy – Average Cost of Single Treatment Cycle and Full Treatment of Metastatic Melanoma (US$), January’2020
Figure 16-13: Yervoy – Average Cost of Single Treatment Cycle, Initial Year and Remaining Years for Management of Metastatic Melanoma (US$), January’2020
Figure 16-14: Yervoy – Duration of Single Treatment Cycle and Full Treatment in Combinational Therapy (Weeks), January’2020
Figure 16-15: Yervoy – Average Cost of Single Treatment Cycle and Full Treatment in Combinational Therapy (US$), January’2020
Figure 16-16: Yervoy – Annual Sales Value (US$ Billion), 2016-2018
Figure 16-17: Yervoy – Quarterly Sales Value (US$ Million), Q1-Q3, 2018 and 2019
Figure 16-18: US - Yervoy Quarterly Sales Value (US$ Million), Q1-Q3, 2018 and 2019
Figure 16-19: Yervoy – US v/s Rest of World Sales Share (%), Q1-Q3, 2019
Figure 16-20: Opdivo - Patent Expiration Year by Region
Figure 16-21: Opdivo - Price for 4ml Supply and Price per ml of 10mg/ml Intravenous Injection (US$), January’2020
Figure 16-22: Opdivo - Price for 10 ml Supply and Price per ml of 10mg/ml Intravenous Injection (US$), January’2020
Figure 16-23: Opdivo - Price for 20 ml Supply and Price per ml of 10mg/ml Intravenous Injection (US$), January’2020
Figure 16-24: Opdivo Monotherapy Therapy - Single Treatment Cycle and Full Treatment Average Cost (US$), January’2020
Figure 16-25: Opdivo Combination – Dose for Management of Melanoma and Renal Cell Carcinoma (mg/3 Weeks)), January’2020
Figure 16-53: US - Libtayo Quarterly Sales Value (US$ Million), Q1-Q3, 2019
Figure 16-54: Libtayo – 9 Month Sales Share – US v/s Rest of World (%), Q1-Q3, 2019
Figure 16-55: Libtayo – 9 Month Sales of US v/s Rest of World (US$ Million), Q1-Q3, 2019
Figure 17-1: Herceptin – Approval Year by Cancer Type
Figure 17-2: Herceptin – Price for a Supply of 10 and Price for Single 150mg Powder for Injection (US$), January’2020
Figure 17-3: Herceptin – Initial and Maintenance Dose for Breast Cancer Treatment (mg/kg), January’2020
Figure 17-4: Herceptin – Cost of Initial Dose, Maintenance Dose and Annual Treatment Cost of Breast Cancer (US$), January’2020
Figure 17-5: Herceptin – Initial and Maintenance Dose for Adjuvant Breast Cancer, Gastric and Esophageal Carcinoma (mg/kg), January’2020
Figure 17-6: Herceptin – Cost of Initial Dose, Maintenance Dose and Annual Treatment Cost of Adjuvant Breast Cancer, Gastric and Esophageal Carcinoma (US$), January’2020
Figure 17-7: Herceptin – Annual Sales Value (US$/CHF Billion), 2017 and 2018
Figure 17-10: US - Herceptin – Quarterly Sales Value (US$ Billion), Q1-Q3, 2018 and 2019
Figure 17-11: Herceptin – Sales Value – US v/s ROW (US$ Billion), 2018
Figure 17-12: Herceptin –Sales Share by Region (%), 2018
Figure 17-13: Avastin – Price for a Supply of 10 and Price for Single 4ml Solution for Injection (US$), January’2020
Figure 17-14: Avastin – Price for a Supply of 10 and Price for Single 16ml Solution for Injection (US$), January’2020
Figure 17-15: Avastin – Cost of Single Treatment Cycle and Annual Treatment Cost for NSCLC and Metastatic Cervical Cancer (US$), January’2020
Figure 17-16: Avastin – Cost of Single Treatment Cycle and Annual Treatment Cost for Recurrent Glioblastoma and Renal Cell Carcinoma (US$), January’2020
Figure 17-17: Avastin – Duration of Treatment of Recurrent Glioblastoma and Renal Cell Carcinoma as Combinational and Monotherapy (Weeks), January’2020
Figure 17-18: Avastin – Cost of Single Treatment Cycle and Annual Treatment Cost for Recurrent Glioblastoma and Renal Cell Carcinoma (US$), January’2020
Figure 17-19: Avastin – Annual Sales Value (US$/CHF Billion), 2017 and 2018
Figure 17-20: Avastin – Quarterly Sales Value (US$ Billion), Q1-Q3, 2018 and 2019
Figure 17-21: US - Avastin – Quarterly Sales Value (US$ Million), Q1-Q3, 2018 and 2019
Figure 17-22: Avastin – 9 Month Sales Share by Region (US$ Billion), Q1-Q3, 2019
Figure 17-23: Avastin – 9 Month Sales Share of US and Rest of World (%), Q1-Q3, 2019
Figure 17-24: Rituxan – Price for a Supply of 10 ml and Price per ml of Solution for Injection (US$), January’2020
Figure 17-25: Rituxan – Price for a Supply of 50 ml and Price per ml of Solution for Injection (US$), January’2020
Figure 17-26: Rituxan – Price for a Supply of 100 ml and Price per ml of Solution for Injection (US$), January’2020
Figure 17-27: Rituxan – Average Minimum and Maximum Cost for Refractory CD20+ B-Cell NHL (US$), January’2020
Figure 17-28: Rituxan – Average Cost for Single Dose and Cost of Full Maintenance Phase for Non-Progressing CD20+ B-Cell NHL (US$), January’2020
Figure 17-29: Rituxan – Annual Sales Value (US$/CHF Billion), 2017 and 2018
Figure 17-30: Rituxan – Quarterly Sales Value (US$ Billion), Q1-Q3, 2018 and 2019
Figure 17-31: US - Rituxan – Quarterly Sales Value (US$ Billion), Q1-Q3, 2019
Figure 17-32: Avastin – 9 Month Sales Share of US and Rest of World (%), Q1-Q3, 2019
Figure 17-33: Rituxan – 9 Month Sales Share by Region (CHF/US$ Billion)), Q1-Q3, 2019
Figure 17-34: Rituxan – 9 Month Sales Share by Region (%), Q1-Q3, 2019
Figure 17-35: Erbitux - Approval Year by Cancer Type
Figure 17-36: Erbitux - Price for a Supply of 50 ml and Price per ml of Intravenous Solution (US$), January’2020
Figure 17-37: Erbitux - Price for a Supply of 100 ml and Price per ml of Intravenous Solution (US$), January’2020
Figure 17-38: Erbitux – Initial and Maintenance Dose for Colorectal, Head and Neck Cancer Treatment (mg/ m2), January’2020
Figure 17-39: Erbitux – Average Cost of Initial Dose, Maintenance Dose and Cost of Annual Treatment (US$), January’2020
Figure 17-86: US - Perjeta – Quarterly Sales Value (US$ Million), Q1-Q3, 2019
Figure 17-87: Perjeta – Sales Value by Region (US$/CHF Million), Q1 – Q3, 2019
Figure 17-88: Perjeta – Sales Value by Region, Q1 – Q3, 2019
Figure 18-1: Blincyto - Number of Induction and Consolidation Cycles for Treatment of MRD+ B-cell precursor ALL, January’2020
Figure 18-2: Blincyto - Duration of Treatment Phase and Resting Phase in Induction and Consolidation Cycles for Treatment of MRD+ B-cell Precursor ALL (Days) , January’2020
Figure 18-3: Blincyto - Cost of Single Cycle and Full Treatment Cost of MRD+ B-cell precursor ALL (US$), January’2020
Figure 18-4: Blincyto - Recommended Number of Induction and Consolidation Treatment Cycle for Relapsed B-Cell Precursor ALL, January’2020
Figure 18-5: Blincyto - Duration of Single Induction, Consolidation, Continued Cycle and Full Treatment for Relapsed B-Cell Precursor ALL (Weeks), January’2020
Figure 18-6: Blincyto - Cost of 1st and 2nd Induction Cycle for Treatment of Relapsed B-Cell Precursor ALL (US$), January’2020
Figure 18-7: Blincyto - Cost of Different Treatment Phases and Full Treatment Cost for Relapsed B-Cell Precursor ALL (US$), January’2020
